Currently, the primary treatment for wet AMD is anti-VEGF mAb therapeutics.[17] Similarly, an anti-HTRA1 therapeutic would result in a decrease in VEGF expression, thereby slowing or halting choroidal neovascularization. The gene discussed is HTRA1; the disease is wet macular degeneration.